Leqembi & Kisunla: New Alzheimer's Treatments Explained | Dr. Armen J. Moughamian

Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. Dr. Armen J. Moughamian, a neurologist and medical director of the Ray Dolby Brain Health Center at Sutter Health, joins this episode to answer common questions about what these new therapies can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access. To learn more, watch our full conversation with Dr. Moughamian, part of the Zoom In on Dementia and Alzheimer’s series. Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech. Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.